Results 71 to 80 of about 39,275 (210)

GLP-1 Receptor Agonist

The Journal of Korean Diabetes
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by food intake from L cells of the ileum. GLP-1 contributes to blood glucose control through three main mechanisms: promoting glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon hypersecretion from pancreatic alpha cells, and delaying gastric emptying time.
openaire   +1 more source

GLP-1 receptor agonists and conscious sedation

Interventional Pain Medicine
This FactFinder presents a brief summary of the evidence and outlines recommendations regarding periprocedural management of patients on glucagon-like peptide-1 receptor agonists (GLP-1RA) therapy undergoing elective pain procedures under conscious sedation.
Eric K. Holder, Amelia Ni, David Levi
openaire   +2 more sources

A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. [PDF]

, 2014
It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals, ω-3-FAs have a number of health benefits ascribed ...
Akiyama, Taro E, Armando, Aaron M, Bogner-Strauss, Juliane G, Chi, Tyler J, Chung, Heekyung, Cox, Jason M, Di Salvo, Jerry, Evans, Ronald M, Hah, Nasun, Lackey, Denise, Lagakos, William S, McNelis, Joanne, Oh, Da Young, Olefsky, Jerrold M, Pessentheiner, Ariane R, Powels, Mary Ann, Quehenberger, Oswald, Sasik, Roman, Sinz, Christopher, Walenta, Evelyn, Watkins, Steven M   +20 more
core   +1 more source

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial [PDF]

, 2016
_Aims/hypothesis:_ Glucagon-like peptide (GLP)-1-based therapies have been suggested to improve hepatic steatosis. We assessed the effects of the GLP-1 receptor agonist liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin on hepatic ...
Bos, I.C. (Indra) van den, Cahen, D.L. (Djuna), Diamant, M. (Michaela), Hoekstra, T. (Trynke), Kramer, M.H.H. (Mark), Muskiet, M.H.A. (Marcel H. A.), Pouwels, P.J.W. (Petra), Smits, M.M. (Mark M.), Tonneijck, L. (Lennart), van Raalte, D.H. (Daniël H.)   +9 more
core   +1 more source

Truncated glucagon-like peptide-1 and exendin-4 α-conotoxin pl14a peptide chimeras maintain potency and α-helicity and reveal interactions vital for cAMP signaling in vitro [PDF]

, 2016
Glucagon-like peptide-1 (GE P-1) signaling through the glucagon-like peptide 1 receptor (GLP-1R) is a key regulator of normal glucose metabolism, and exogenous GLP-1R agonist therapy is a promising avenue for the treatment of type 2 diabetes mellitus. To
Craik, David J., Derksen, David R., Edmonds, David J., Fairlie, David P., Griffith, David A., Liras, Spiros, Loria, Paula M., Mitchell, Justin M., Price, David A., Ruggeri, Roger B., Schroeder, Christina I., Swedberg, Joakim E.   +11 more
core   +1 more source

Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study

The Lancet. Healthy Longevity
Summary: Background: GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by ...
ProfPhD Fei-Yuan Hsiao, Elise Chia-Hui Tan, PhD, Lin-Chieh Meng, MS, Yi-Chin Lin, PharmD MS, Ho-Min Chen, MS, Shang-Ting Guan, PharmD, ProfMD PhD Der-Cherng Tarng, PharmD, ProfMD PhD Chih-Yuan Wang, PharmD, Prof Liang-Kung Chen, PharmD   +8 more
doaj   +1 more source

The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist [PDF]

, 2020
The kappa opioid receptor (κOR) is an important target for pain therapeutics to reduce depression and other harmful side effects of existing medications.
Goddard, William A., III, Kim, Soo-Kyung, Mafi, Amirhossein   +2 more
core   +1 more source

The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell Surface expression [PDF]

, 2014
The hGLP-1R is a target for the treatment of type 2 diabetes and belongs to the class B family of GPCRs. Like other class B GPCRs, the GLP-1R contains an N-terminal signal peptide (SP) and undergoes N-linked glycosylation, which are important for its ...
A Couvineau, B Gallwitz, B Van Eyll, C Parthier, C Rutz, C Widmann, CR Underwood, DJ Drucker, E Wallin, F Maley, GG Holz, GM Whitaker, JC Davies, JCB Davies, JJ Holst, K Hatsuzawa, K Schulz, L Achour, M Alken, M Alken, ME Doyle, MT Duvernay, Q Chen, R Kochl, RS Hegde, S Runge, T Akamizu, T Ban, V Kanamarlapudi, V Kanamarlapudi, Y Huang   +30 more
core   +1 more source

The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. [PDF]

, 2017
ObjectiveThe differential effect of GLP-1 agonist Exenatide on functional connectivity of the nucleus tractus solitaries (NTS), a key region associated with homeostasis, and on appetite-related behaviours was investigated in women with normal weight ...
Connolly, L, Coveleskie, K, Gupta, A, Kilpatrick, LA, Labus, JS, Mayer, EA, Sanmiguel, C, Stains, J   +7 more
core   +3 more sources

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review

EClinicalMedicine
Summary: Despite the availability of a wide range of antihypertensive agents, a significant proportion of individuals with resistant hypertension (RHTN) struggle to achieve blood pressure (BP) control.
Candace Jarade, Tetiana Zolotarova, Areesha Moiz, Mark J. Eisenberg   +3 more
doaj   +1 more source